skip to main content

Karpas 707

Karpas 707

Catalogue No.

22110801

Cell Line Name

Karpas 707

Cell Line Description

Karpas 707 is a human plasmacytoma cell line that was established from the peripheral blood of a 53-year-old Caucasian male who was diagnosed with multiple myeloma.

General Info

Species

Human

Unique to ECACC

Yes

Nagoya Status

Not Applicable

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Tissue of Origin

Bone marrow aspirate and peripheral blood

Morphology

Single round to polymorphic cells growing in suspension

DNA profile (STR Profile)

Amelogenin: X,X
CSF1PO: 11,13
D3S1358: 14,17
D5S818: 11,11
D7S820: 10,10
D8S1179: 11,12
D13S317: 9,9
D16S539: 11,12
D18S51: 11,15
FGA: 18,23
Penta D: 9,10
Penta E: 9,10
TH01: 9,9
TPOX: 9,11
vWA: 20,21

Applications

Oncology research.

Disease

Myeloma/Plasmacytoma

Culture Conditions

Cell Type

B Lymphocyte – White blood cell

Subculture Routine

Maintain cultures between 5x104 and 9x105 cells per ml.

Doubling time approximately 60 hours. Subculture every 2-4 days
5% CO2, 37°C
When using Corning plasticware, many of the these cells attach to the plastic but will keep dividing and releasing cells into the culture media.

Cells may be removed by tapping gently or by using EDTA.

Culture Medium

RPMI1640 + 10% Foetal Bovine Serum (FBS) + 2mM L-Glutamine 

Growth Mode

Suspension

Additional Info

Depositor

Dr Amanda Zeffman (on behalf of Professor Abraham Karpas), Cambridge Enterprise, University of Cambridge. ORIGINATOR: Professor Abraham Karpas, University of Cambridge

Country of Origin

United Kingdom

GMO Status

Not Applicable

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Karpas A., Fischer P., Swirsky D. Human myeloma cell line carrying a Philadelphia chromosome. Science 216:997-999(1982) PubMed=7079750 DOI: 10.1126/science.7079750

Bibliography

Karpas A., Viruses and human leukemia in vitro. (In) Human leukemia. Cytochemical and ultrastructural techniques in diagnosis and research. Developments in Oncology, Vol. 14; Polliack A. (eds.); pp.495-526; Martinus Nijhoff Publishing; Boston (1984) PubMed=3332852 

DOI: https://doi.org/10.1007/978-1-4613-2823-0_29

A. Karpas, in The Role of Viruses in Human Cancer, G. Giraldo and E. Beth (Elsevier/North-Holland, Amsterdam, 1980), pp. 185-203.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: Karpas 707 (ECACC 22110801).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

 

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.